Undiagnosed prediabetes status is associated with a reduced effectiveness of phosphodiesterase type 5 inhibitors in men with erectile dysfunction

The efficacy of phosphodiesterase type 5 inhibitors (PDE5i) in patients with erectile dysfunction (ED) and undiagnosed prediabetes (PreDM) has been scantly analysed. We aimed to assess rates of and predictors of response to oral treatment in a cohort of ED men naïve for PDE5i with either normo-glyca...

Full description

Saved in:
Bibliographic Details
Published in:International journal of impotence research 2020-07, Vol.32 (4), p.393-400
Main Authors: Boeri, Luca, Capogrosso, Paolo, Ventimiglia, Eugenio, Pozzi, Edoardo, Chierigo, Francesco, Belladelli, Federico, Zuabi, Rani, Schifano, Nicolò, Abbate, Costantino, Dehò, Federico, Montanari, Emanuele, Montorsi, Francesco, Salonia, Andrea
Format: Article
Language:English
Subjects:
692/499
692/699/2768/1575
Cohort Studies
Complications and side effects
Diabetes
Diagnosis
Drug therapy
Enzyme inhibitors
Erectile dysfunction
Erectile Dysfunction - diagnosis
Erectile Dysfunction - drug therapy
Health risk assessment
Humans
Impotence
Male
Medical diagnosis
Medicine
Medicine & Public Health
Mens health
Patient outcomes
Phosphodiesterase 5 Inhibitors - therapeutic use
Prediabetic state
Prediabetic State - complications
Prediabetic State - diagnosis
Prediabetic State - drug therapy
Reproductive Medicine
Risk factors
rology
Testosterone
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of phosphodiesterase type 5 inhibitors (PDE5i) in patients with erectile dysfunction (ED) and undiagnosed prediabetes (PreDM) has been scantly analysed. We aimed to assess rates of and predictors of response to oral treatment in a cohort of ED men naïve for PDE5i with either normo-glycaemia or PreDM or diabetes mellitus (DM). Complete data from 466 men were analysed. Comorbidities were scored with the Charlson Comorbidity Index (CCI). Patients completed the International Index of Erectile Function (IIEF) at baseline and after 3 months of PDE5i treatment. Treatment response was evaluated using the minimal clinically important difference (MCID) (mild: +2; moderate: +5; severe: +7 from baseline IIEF-EF). PreDM status was defined as for the American Diabetes Association (2015) criteria. Descriptive statistics and logistic regression models tested the association between clinical predictors and MCID response. Overall, 253 (56.7%), 105 (23.5%) and 88 (19.7%) patients had normo-glycaemia (=controls), PreDM and DM, respectively. Diabetic and PreDM men were older, had higher BMI, higher CCI scores and lower total testosterone (tT) (all p  
ISSN:0955-9930
1476-5489
DOI:10.1038/s41443-019-0149-4